MCRPC
Clinical trials for MCRPC explained in plain language.
Never miss a new study
Get alerted when new MCRPC trials appear
Sign up with your email to follow new studies for MCRPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising prostate cancer drug gets extended trial for those already benefiting
Disease control ENROLLING_BY_INVITATIONThis trial gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694, often combined with enzalutamide (Xtandi), if they are already seeing benefits from it in a previous study. About 40 participants will be enrolle…
Matched conditions: MCRPC
Phase: PHASE1, PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug combo aims to slow tough prostate cancer
Disease control OngoingThis Phase 3 trial tests whether adding talazoparib to enzalutamide can slow the spread of metastatic castration-resistant prostate cancer (mCRPC). About 1,054 men with this advanced cancer are taking either the drug combo or a placebo plus enzalutamide. The study tracks how long…
Matched conditions: MCRPC
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody combo aims to control hard-to-treat prostate cancer
Disease control OngoingThis early-stage trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC) — a type that has stopped responding to hormone therapy. Seven men with advanced disease will receive the combinati…
Matched conditions: MCRPC
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC